The PPARγ agonist rosiglitazone has been shown to inhibit mesangial cell proliferation, serine protease activity, and TGFβ expression, while activating the TGFβ-Smad3 signaling pathway, thereby preventing the progression of glomerular sclerosis [41]. Here, SMAD3 is linked to Glomerular sclerosis.